Pacific Financial Statements From 2010 to 2025
| PFGTF Stock | USD 0.1 0.00 0.00% |
Check Pacific Edge financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pacific Edge's main balance sheet or income statement drivers, such as , as well as many indicators such as . Pacific financial statements analysis is a perfect complement when working with Pacific Edge Valuation or Volatility modules.
Pacific |
Pacific Edge Limited Company Return On Equity Analysis
Pacific Edge's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Pacific Edge Return On Equity | -0.22 |
Most of Pacific Edge's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pacific Edge Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Pacific Edge Limited has a Return On Equity of -0.2224. This is 99.07% lower than that of the Healthcare sector and 96.67% lower than that of the Diagnostics & Research industry. The return on equity for all United States stocks is 28.26% lower than that of the firm.
Pacific Edge Limited Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pacific Edge's current stock value. Our valuation model uses many indicators to compare Pacific Edge value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pacific Edge competition to find correlations between indicators driving Pacific Edge's intrinsic value. More Info.Pacific Edge Limited is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pacific Edge's earnings, one of the primary drivers of an investment's value.About Pacific Edge Financial Statements
Pacific Edge stakeholders use historical fundamental indicators, such as Pacific Edge's revenue or net income, to determine how well the company is positioned to perform in the future. Although Pacific Edge investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pacific Edge's assets and liabilities are reflected in the revenues and expenses on Pacific Edge's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pacific Edge Limited. Please read more on our technical analysis and fundamental analysis pages.
Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore. Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand. PACIFIC EDGE operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 86 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Pacific Pink Sheet
Pacific Edge financial ratios help investors to determine whether Pacific Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pacific with respect to the benefits of owning Pacific Edge security.